Park Jong Mi, Lee Sang Chul, Ham Chorom, Kim Yong Wook
Department and Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, 50-1 Yonsei-Ro, Seodaemun-Gu, Seoul, 03722, Republic of Korea.
Gut Pathog. 2023 Mar 6;15(1):9. doi: 10.1186/s13099-023-00536-1.
Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide. Gut dysbiosis is hypothesized to cause PD; therefore, whether probiotics can be used as adjuvants in the treatment of PD is being actively investigated.
We performed a systematic review and meta-analysis to evaluate the effectiveness of probiotic therapy in PD patients.
PUBMED/MEDLINE, EMBASE, Cochrane, Scopus, PsycINFO and Web of Science databases were searched till February 20, 2023. The meta-analysis used a random effects model and the effect size was calculated as mean difference or standardized mean difference. We assessed the quality of the evidence using the Grade of Recommendations Assessment, Development and Evaluation (GRADE) approach.
Eleven studies involving 840 participants were included in the final analysis. This meta-analysis showed high-quality evidence of improvement in Unified PD Rating Scale Part III motor scale (standardized mean difference [95% confidence interval]) (- 0.65 [- 1.11 to - 0.19]), non-motor symptom (- 0.81 [- 1.12 to - 0.51]), and depression scale (- 0.70 [- 0.93 to -0.46]). Moderate to low quality evidence of significant improvement was observed in gastrointestinal motility (0.83 [0.45-1.10]), quality of life (- 1.02 [- 1.66 to - 0.37]), anxiety scale (- 0.72 [- 1.10 to - 0.35]), serum inflammatory markers (- 5.98 [- 9.20 to - 2.75]), and diabetes risk (- 3.46 [- 4.72 to - 2.20]). However, there were no significant improvements in Bristol Stool Scale scores, constipation, antioxidant capacity, and risk of dyslipidemia. In a subgroup analysis, probiotic capsules improved gastrointestinal motility compared to fermented milk.
Probiotic supplements may be suitable for improving the motor and non-motor symptoms of PD and reducing depression. Further research is warranted to determine the mechanism of action of probiotics and to determine the optimal treatment protocol.
帕金森病(PD)是全球第二常见的神经退行性疾病。肠道微生物群失调被认为会导致帕金森病;因此,益生菌是否可作为帕金森病治疗的辅助药物正在积极研究中。
我们进行了一项系统评价和荟萃分析,以评估益生菌疗法对帕金森病患者的有效性。
检索了截至2023年2月20日的PUBMED/MEDLINE、EMBASE、Cochrane、Scopus、PsycINFO和Web of Science数据库。荟萃分析采用随机效应模型,效应大小计算为平均差或标准化平均差。我们使用推荐分级评估、制定和评价(GRADE)方法评估证据质量。
最终分析纳入了11项研究,共840名参与者。该荟萃分析显示,有高质量证据表明统一帕金森病评定量表第三部分运动量表(标准化平均差[95%置信区间])(-0.65[-1.11至-0.19])、非运动症状(-0.81[-1.12至-0.51])和抑郁量表(-0.70[-0.93至-0.46])有所改善。在胃肠动力(0.83[0.45 - 1.10])、生活质量(-1.02[-1.66至-0.37])、焦虑量表(-0.72[-1.10至-0.35])、血清炎症标志物(-5.98[-9.20至-2.75])和糖尿病风险(-3.46[-4.72至-2.20])方面观察到中等至低质量的显著改善证据。然而,布里斯托大便分类法评分、便秘、抗氧化能力和血脂异常风险没有显著改善。在亚组分析中,与发酵乳相比,益生菌胶囊改善了胃肠动力。
补充益生菌可能适合改善帕金森病的运动和非运动症状并减轻抑郁。有必要进一步研究以确定益生菌的作用机制并确定最佳治疗方案。